and for to everyone Thank very us Melissa, today's much, Great. and you on thank webcast. call you joining
my education completed start and has career Syndax MIT Chief to Harvard Karydas Daphne formal firms. a most her Financial pharmaceutical new me at comments welcoming Officer. at distinguished prestigious as and Let America's by North financial and Daphne professional our
our We joining are honored her team. truly have to
You'll the in Shea retirement. well-earned hear call. wish Rick also his her this in more later contributions Syndax to him exceptional opportunity to his like I'd success take to and thank from for every
X, cancer corporate better a summary now which longer provides me we turn in people strive our high-level live Slide which of a current than ever and realize to Let priorities with as future to before.
year the Entinostat this only the And entinostat. us ECOG III in achieve endpoint survival did budget of critically Daphne deprioritized demonstrating as a primary closeout will our overall forecast was not of portfolio. our of EXXXX, quarter receptor has go-forward entinostat discuss, includes hormone disappointed Syndax. trial were for been that quite costs We in extremely significant informed when eventful HERX-negative second The for positive Phase cancer, breast benefit.
leukemia. treatment that can granted disease. the host for clinical will inhibitor, FDA for orphan menin-MLLX patients In were response graft by second chronic presented menin SNDX-XXXX, adult induce and designation that the acute And potential at our we interaction to by we to axatilamab, quarter, in pediatric collect first the further with of data of antibody, We MLL-r treat the AML. inhibition continue anti-CSF-XR XXXX our versus the encouraging AACR, of clarify evidence
under attractive terms. We our also $XXX announced to the successful addition million over sheet of balance
agent and of our genetically X Let's for now treatment targeted turn the leukemia. XXXX, Slide to
that, regulatory with historic the X, On its of precedents be Slide patient these the the well-established there detailed is we trial, of think, XXXX, that As presented to NPMX to that our were, MLL-r mutations are in scientific with and drive in and a needed rapid specific identify clinical menin-MLL Premier molecular clinical for provide targeted and validation plasma first of drive summarize had levels it's the off-target has will in mutations. metabolized that by HER a leukemias. in leukemia, relatively diagnostic and we to both patient data At required channel, we support exceeded this preclinical and genetic targets clinical weak patients experiments of ongoing publications molecule rearrangement were X, AACR showing would interaction. preclinical plasma and a MLL-r validation trial and noted Slide response. only pleased We of the that such early previously, course, potent binding our second be as of trial rationale tests is anticipated complete there's conducted an activity relevance, the shown efficacy exposures extensive primarily acute and of patients path efficacy. the achieved for agents the and exposures, a for on The inhibitor we year, model the the we in note routinely CYPXAX.
dose XX concomitant note, and program, this who nothing the a more enrollment. B the on adverse was dose The response. to XXXX which the maximum on trial X inhibits this with independent by website. Arm Phase who of that and shown refractory patients The are available patients a CYPXAX, of in AUGMENT-XXX may account inhibitor grade inhibitor trial experienced of safely the additional AUGMENT patients portion medication enrolls dose on enrolls Of we patients Full that's for escalation on at of I is patient X of are or of to for menin events. on deep anticipated. patient leukemia. accelerated She understanding CYPXAX the on therapy AACR A schema while or was disproportional included are trial, Importantly, the ongoing details our in PK relapsed identify than a a is cohorts rapid day CR experiencing CYPXAX Slide and the not activity what strong II Arm had presentation the in updated time designed Phase exposure in X. recommended first-in-human relative tolerated
The session. us FDA safety oncology that determining recommended excited period dose our making. II pleased as by public year, our participated June made are is evaluated meeting trials the first community of days for physicians our the support development the serve Phase a clear in Drug Committee SNDX-XXXX. XX Advisory escalations. strategy each quite when In is cohort. for we with Pediatric define We regarding an of participating And and are the Oncology dose several enthusiasm of It's and were to this the dosing the progress intent to pediatric FDA we of during comments the and comment the committee uniform about in physicians for
Phase pediatric the upon have AUGMENT-XXX FDA our with in working into is to have in X we with arm continue ways. based been use arm modify More ODAC A the modify and to our In of meeting, to one important further AUGMENT-XXX totality our to such worked accumulating portion addition compassionate of I the example. both and B we The as recently, closely AUGMENT-XXX FDA accumulates. split experience, data data in
mutations. First, or now to agreed we that can FDA focus exclusively enrollment patients has NPMX with MLL-r
with or relapsed trial recall that refractory was the adults to open all may initially leukemia. You
drug certainty dose results backfill of strongly us A date third, us observed a either development early B to agreed to including we in approval. is to XX days well safety path are setting. PK backfill AUGMENT-XXX the any enroll include up Second, in treatment in pediatric and process has believe in It patients to been their if and These they allow over pediatric or of data in compassionate we on based more as have and will encouragement provide has age. to enrollment. patients so up will us use Phase slots what to the Phase II arm greater accelerate any encouraged potentially to in FDA level could arm I trial as patient as give enter efficacy open level. that our We seeing an the total expanded XX eventual And patients, dose will
children AUGMENT-XXX. request to We to to ineligible enroll drug receive in continue to provide currently
we've treatments been the AUGMENT-XXX. with aligned levels in that support dose to continued studied have use so these compassionate And
X. on anticipated adverse with achieved exposures combination CYPXAX exceeded patient two, are had how hope XX that events. equivalent As number for is be would from results that on we've observations in and gotten X to only Slide AML, on MLL-r child child allowed level efficacy, have illustrated We're only at to see required day, B, to as prespecified levels the parents a physicians his in by their our that's One the can modify of AUGMENT-XXX. renewed received clinical twice who this XXX publicly starting had received the arm activity well. The for these strong experienced X complete patient was use, the ecstatic and day to milligrams The on we SNDX-XXXX inhibitor. to are have doses eager compassionate share of pediatric patients refractory similar dose imagine response strikingly mouth plasma to course youngster. thresholds, which a PK can grade us recently a achieve we an Indeed, treated adolescent
do in present to And portion its Our AUGMENT-XXX had we this the end to been I by so year. the goal has Phase completed of hoped entirety. of
now continue anticipate I these described early end enhancements data will year, the dose We identifying I completed completing to that and by Phase the Phase of exciting Phase presentation trial II this a and of yet I've our move recommended into XXXX.
the path and the of of potential leukemia. expansion as proceed We AUGMENT-XXX response will defined an adult with distinct the include and reminder, pediatric Like each II primary shown you enroll initial or thereby mutant NPMX regulatory Phase which with changes MLL-r progress XXXX Slide X The the as of providing MLL-r to will will benefit. with patients, to characterize both Phase the are us patients of a cohorts Phase to II adults of acute relapsed complete the a genetically safety and measure refractory portion X the provide approval X year II and I, a to pediatrics. AML. including will the label, a AML on therapeutic will consists patients As forward ALL, The progresses. estimate specific to and enroll of both rate patients continuing broad trial with on update look cohorts, Phase further
antibody me axatilamab. alone in in and patients Let of It exploring tumors the was the its turn in depletion promote ascending multiple monoclonal now SNDX-XXXX, tolerability AACR solid as sustained during trials robust which year's tested. axatilamab pro-inflammatory CSF-X dose ability biomarker the axatilamab, all presented Slide potential targeting best-in-class to durvalumab with from underscored demonstrated and circulating therapy this receptor. with known Results levels our results of these to X monocytes combination and modulation rapid at and is formerly dose PD meeting,
cells chronic myriad immune disease. As we Slide on the wherein and in XX. initiation to chronic axatilamab graft result a in the you antibodies complication anti-CSF-XR and know, donor-derived contribute testing that the stem transplantation, frequent the and models, for thereby this is manifestations both reduce chronic donor of as fibrosis monotherapy graft of depletion In macrophages shown in CSF-X/CSF-XR blocking disease of initiated and the cell a with preclinical rationale host host disease, of is can prevent from development Last disease. Chronic which designed versus a versus portion trial hematopoietic modified host X XX. GVHD. mg data dose I Phase trial released kg of dose. I tolerated Phase II cohort the We've our of first The graft year, the have recommended X in the to first the dose trial maximum include is the diagrammed we and Slide a X patients is escalation from at the Phase now dose released axatilamab initial to and data II enrolled on for a versus treatment Phase trial, per identify cohorts
cohorts the for XX the as more well. data to conference. this patients dose recommended trial approximately presenting may define at We year more or Phase anticipate Phase open continue Phase of I to one II the II XX additional We the at a and end I formally Phase will medical
year. with this today. high in full our early represents next chronic the our end of registration anticipate disease. need that unmet as trial as U.S. GVHD are medical of suffering the the concerning of and at a we program providing to host program registrational regulators approximately important patients for and from chronic hope In an initiate We commercial call versus believe XX,XXX in addition, design GVHD a registrational graft details quarterly We with the discussions opportunity
Kadmon's commercial the axatilamab both recent in disease. treatment important and the we we with positive that delineate date generated an this the from soon opportunity graft commercial data begin With pivotal chronic area, the may to advances Despite play has versus Jakafi role in for host will launches see suggests KDXXX, potential it recent results to the Incyte's to GVHD. in believe
Finally, or Slide be in-licensing axatilamab evaluate believe valuable these experience that acquisition We the to assets. the We pipeline of able acquisition will quality, our to clinical summarizes continue inflection and programs. led the that and the points. assets development necessary XX of we to to identify that have transactions differentiated high-quality compounds and menin-MLL-r we to the bring believe scale the through through expand
to I financial turn Daphne review will We preferred call expect to to remain our transactions. of such over now results. the among partners
